JP2022500465A - ペプチドおよびその医学的使用 - Google Patents

ペプチドおよびその医学的使用 Download PDF

Info

Publication number
JP2022500465A
JP2022500465A JP2021514627A JP2021514627A JP2022500465A JP 2022500465 A JP2022500465 A JP 2022500465A JP 2021514627 A JP2021514627 A JP 2021514627A JP 2021514627 A JP2021514627 A JP 2021514627A JP 2022500465 A JP2022500465 A JP 2022500465A
Authority
JP
Japan
Prior art keywords
cysteine
tumor
angiogenesis
peptide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514627A
Other languages
English (en)
Japanese (ja)
Inventor
ルーボ メノッティ
ロジエッロ ダビデ
デファルコ サンドロ
Original Assignee
アンビション ソチエタ レスポンサビリタ リミタータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンビション ソチエタ レスポンサビリタ リミタータ filed Critical アンビション ソチエタ レスポンサビリタ リミタータ
Publication of JP2022500465A publication Critical patent/JP2022500465A/ja
Priority to JP2024128153A priority Critical patent/JP2024150757A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021514627A 2018-09-11 2019-09-11 ペプチドおよびその医学的使用 Pending JP2022500465A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024128153A JP2024150757A (ja) 2018-09-11 2024-08-02 ペプチドおよびその医学的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000008493 2018-09-11
IT201800008493 2018-09-11
PCT/IB2019/057636 WO2020053772A1 (en) 2018-09-11 2019-09-11 Peptides and medical uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024128153A Division JP2024150757A (ja) 2018-09-11 2024-08-02 ペプチドおよびその医学的使用

Publications (1)

Publication Number Publication Date
JP2022500465A true JP2022500465A (ja) 2022-01-04

Family

ID=64607074

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514627A Pending JP2022500465A (ja) 2018-09-11 2019-09-11 ペプチドおよびその医学的使用
JP2024128153A Pending JP2024150757A (ja) 2018-09-11 2024-08-02 ペプチドおよびその医学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024128153A Pending JP2024150757A (ja) 2018-09-11 2024-08-02 ペプチドおよびその医学的使用

Country Status (8)

Country Link
US (1) US12441765B2 (enExample)
EP (1) EP3849582B1 (enExample)
JP (2) JP2022500465A (enExample)
KR (1) KR20210062649A (enExample)
CN (1) CN112996528B (enExample)
AU (1) AU2019337806B2 (enExample)
CA (1) CA3112169A1 (enExample)
WO (1) WO2020053772A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500463A (ja) * 2018-09-11 2022-01-04 アンビション ソチエタ レスポンサビリタ リミタータ ペプチドおよびその医学的使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085796A2 (en) * 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510688A (ja) * 1993-12-15 1997-10-28 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｃｘｃインタークリン分子のペプチド阻害剤
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
CA2695960A1 (en) * 2007-08-08 2009-03-12 The Board Of Regents Of The University Of Texas System Vegfr-1/nrp-1 targeting peptides
EP2723766A4 (en) * 2011-06-22 2015-05-20 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
BR112017018665A2 (pt) * 2015-03-02 2018-04-24 The Board Of Trustees Of The University Of Illinois peptídeos para inibição de angiogênese
US10463710B2 (en) * 2015-04-27 2019-11-05 Mackay Memorial Hospital Short synthetic peptide for the treatment and/or prophylaxis of autoimmune and inflammatory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085796A2 (en) * 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. PONTICELLI, ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 49, JPN6023026818, 2008, pages 34250 - 34259, ISSN: 0005295339 *
V. CICATIELLO, ET AL., ONCOTARGET, vol. 6, no. 12, JPN6023026817, 2015, pages 10563 - 10576, ISSN: 0005295340 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500463A (ja) * 2018-09-11 2022-01-04 アンビション ソチエタ レスポンサビリタ リミタータ ペプチドおよびその医学的使用

Also Published As

Publication number Publication date
EP3849582B1 (en) 2025-12-31
WO2020053772A1 (en) 2020-03-19
JP2024150757A (ja) 2024-10-23
AU2019337806B2 (en) 2025-08-14
CA3112169A1 (en) 2020-03-19
KR20210062649A (ko) 2021-05-31
US20220064216A1 (en) 2022-03-03
EP3849582A1 (en) 2021-07-21
CN112996528B (zh) 2025-01-07
US12441765B2 (en) 2025-10-14
AU2019337806A1 (en) 2021-05-13
CN112996528A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
JP2019069942A (ja) ペプチド治療薬およびその使用方法
JP2022514778A (ja) 筋膜損傷の予防および治療におけるアネキシンの使用
US20200306244A1 (en) Wnt inhibitors for use in the treatment of fibrosis
JP2024150757A (ja) ペプチドおよびその医学的使用
CA2739083C (en) Translocation interfering toll-like receptor 3(tlr3) variants for suppressing toll-like receptor activity and uses thereof
US8927498B2 (en) Compositions and methods useful in enhancement of memory
JP2022500463A (ja) ペプチドおよびその医学的使用
KR20200116145A (ko) 안 질환의 예방 및 치료를 위한 중성 엔도펩티다제 (NEP) 및 사람 용해성 엔도펩티다제 (hSEP) 억제제
JP7112753B2 (ja) Ｄｓｇ２由来ペプチド
WO2022162030A1 (en) Peptides for inhibiting angiogenesis
CN108697772B (zh) 用于治疗视网膜病的组合物和方法
Chatterjee The mechanism of regulation of fibroblast growth factor-2 (fgf-2) and vascular endothelial growth factor-a (vegf-a) dependent angiogenesis by junctional adhesion molecule-a (jam-a)
HK40000030B (en) Compositions and methods for treating retinopathy
HK40000030A (en) Compositions and methods for treating retinopathy
BR112015020143B1 (pt) Composição tópica farmacêutica no tratamento ocular tópico e/ou na prevenção de doenças neurodegenerativas da retina

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402